Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to b...

por A’Hern, Roger, DeBono, Johann, Sandhu, Shahneen, Kalaitzaki, Eletheria, Usdin, Martine, Hall, Emma E
Publicado 2011